Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your news in US review and approval news in brief: AbbVie Inc. and Genentech Inc.'s Venclexta (venetoclax tablets) has become the seventh drug to score an approval under the FDA's Real-Time Oncology Review pilot for significant supplemental applications.

Several other companies reeled in supplemental approvals as well, including Regeneron Pharmaceuticals Inc.'s eye drug Eylea (aflibercept) for diabetic...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet